BSPM [Biostar Pharmaceuticals,] 8-K: ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF

[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]

By | 2016-02-07T15:53:10+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[ARTICLES OF AMENDMENT TO THE ARTICLES OFORPORATION OF BIOSTAR PHARMACEUTICALS, This is to certify that: SECOND THIRD FOURTH IN WITNESS WHEREOF Biostar Pharmaceuticals, Ronghua Wang Shuang Gong Chief Executive Officer Secretary ex3-1.htm 2 EX-3.1] [BIOSTAR PHARMACEUTICALS TO EFFECT REVERSE STOCKLIT -- XIANYANG, China, April 3, 2012 a result of the reverse stocklit, the number of outstandingmmon shares will be reduced to approximately 9,398,892.Fractional stockholdings will be rounded up to the nearest whole number.The reverse stocklit will affectl stockholders uniformly and will not affect any stockholders ownership percentage of the]

By | 2016-02-07T15:52:17+00:00 April 4th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: (Original Filing)

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By | 2016-03-03T12:11:13+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: FORM 10-K (Mark One) x December 31, 2011

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, Inc. as of December 31, 2011 Subsidiary Place of incorporation Shaanxi Biostar BioTech Ltd. People’s Republic of China Variable interest entities Place of incorporation Shaanxi Aoxing Pharmaceutical Co., Ltd, People’s Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, LLC People’s Republic of China EX-21 2 ex21.htm] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated March 27, 2012 relating to the consolidated financial statements of Biostar Pharmaceuticals, Inc. as of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. (No. 333-161598) We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 8 ex32-2.htm]

By | 2016-03-03T12:12:52+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-K: FORM 10-K (Mark One) x December 31, 2011

[FORM 10-K (Mark One) x December 31, 2011 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [List of subsidiary / variable interest entities of Biostar Pharmaceuticals, of December 31, 2011 Subsidiary Place oforporation Shaanxi Biostar BioTech Peoples Republic of China Variable interest entities Place oforporation Shaanxi Aoxing Pharmaceutical Peoples Republic of China Shaanxi Weinan Aoxing Pharmaceuticals, Peoples Republic of China] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted March 27, 2012 relating to thensolidated financial statements of Biostar Pharmaceuticals, of and for each of the years ended December 31, 2011 and 2010 in the Annual Report on Form 10-K of] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, (No. 333-161598) We herebynsent to theorporation by reference in the Registration Statement on Form S-8 Mazars CPA Limited Certified Public Accountants Hong Kong March 27, 2012 ex23-2.htm 4 EX-23.2] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Zibing Pan, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 7 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 8 EX-32.2]

By | 2016-02-07T15:55:09+00:00 March 27th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K/A: Consent of Independent Registered Public Accounting Firm To

[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, LLC as of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals, Inc. Certified] [Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren Pharmaceuticals, Ltd.) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders’ Equity F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren] [UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or the “Company”), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical Co., Ltd., acquired 100% equity interest (the “Acquisition”) of Shaanxi Weinan Aoxing Pharmaceutical, LLC (formerly Shaanxi Weinan Huaren Pharmaceutical, Ltd.) (“Shaanxi Weinan”) at a cash purchase consideration of RMB61]

By | 2016-03-03T12:16:03+00:00 December 23rd, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K/A: (Original Filing)

[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, LLC as of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals, Inc. Certified] [Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren Pharmaceuticals, Ltd.) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders’ Equity F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren] [UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or the “Company”), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical Co., Ltd., acquired 100% equity interest (the “Acquisition”) of Shaanxi Weinan Aoxing Pharmaceutical, LLC (formerly Shaanxi Weinan Huaren Pharmaceutical, Ltd.) (“Shaanxi Weinan”) at a cash purchase consideration of RMB61]

By | 2016-03-03T12:14:19+00:00 December 23rd, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K/A: (Original Filing)

[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals,] [Shaanxi Weinan Aoxing Pharmaceuticals, (formerly Shaanxi Weinan Huaren Pharmaceuticals,) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders Equity F-4 Statement ofsh Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors] [UNAUDITED PRO FORMANDENSEDMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, (NASDAQ GM: BSPM) (Biostar or thempany), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical acquired 100% equity interest (the Acquisition) of Shaanxi Weinan Aoxing Pharmaceutical, (formerly Shaanxi Weinan Huaren Pharmaceutical,) (Shaanxi Weinan) at ash purchasensideration of RMB61 million (approximately $9.5 million).]

By | 2016-02-07T15:56:30+00:00 December 23rd, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K/A: Consent of Independent Registered Public Accounting Firm To

[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to yourorporation of our audit reportted December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals,] [Shaanxi Weinan Aoxing Pharmaceuticals, (formerly Shaanxi Weinan Huaren Pharmaceuticals,) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders Equity F-4 Statement ofsh Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors] [UNAUDITED PRO FORMANDENSEDMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, (NASDAQ GM: BSPM) (Biostar or thempany), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical acquired 100% equity interest (the Acquisition) of Shaanxi Weinan Aoxing Pharmaceutical, (formerly Shaanxi Weinan Huaren Pharmaceutical,) (Shaanxi Weinan) at ash purchasensideration of RMB61 million (approximately $9.5 million).]

By | 2016-02-07T15:57:04+00:00 December 23rd, 2011|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2011 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T12:18:31+00:00 November 14th, 2011|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar